Asthma Management Medical Slides
Generate publication-quality asthma management lecture slides in 30 seconds. AI-powered content structured for clinical education.
Generate Asthma Management DeckWhy teach Asthma Management?
Asthma affects over 300 million people globally and causes approximately 455,000 deaths annually. The GINA 2023 guidelines fundamentally shifted management by recommending as-needed ICS-formoterol as preferred reliever therapy across all severity steps, eliminating SABA-only treatment. Teaching asthma requires coverage of phenotyping, stepwise therapy, and the expanding role of biologic agents for severe disease.
What AI generates for Asthma Management
Enter “Asthma Management” and SlideCraft generates a complete lecture deck with slides like these.
See it in action
Type any medical topic and watch AI generate a presentation slide in seconds. No signup required.
3 free previews per hour · No account needed
Enter a topic and click Generate to see your AI slide
Asthma Management Presentation FAQ
How should the GINA 2023 stepwise approach be presented in slides?
Present both treatment tracks: Track 1 (preferred) uses as-needed low-dose ICS-formoterol (Steps 1-2) escalating to maintenance-and-reliever therapy (Steps 3-5). Track 2 uses as-needed SABA with maintenance ICS. Emphasize the paradigm shift from SABA-only to ICS-containing reliever — the SYGMA and Novel START trials showed ICS-formoterol PRN reduced exacerbations by 60% versus SABA alone.
What biologic selection criteria should be included for severe asthma?
Present biomarker-guided selection: blood eosinophils ≥150 (mepolizumab, benralizumab), ≥300 (dupilumab), FeNO ≥25 ppb (dupilumab, tezepelumab), total IgE 30-1500 + allergen sensitization (omalizumab). Tezepelumab (anti-TSLP) works across phenotypes regardless of biomarkers per the NAVIGATOR trial. Include the 2023 ERS/ATS guidelines on biologic switching after 4-6 month inadequate response.
How should acute exacerbation severity be taught in presentation format?
Use the GINA severity assessment: mild-moderate (talks in phrases, SpO2 ≥90%, PEF >50%), severe (talks in words, accessory muscles, SpO2 <90%, PEF ≤50%), life-threatening (drowsy/confused, silent chest, SpO2 <90%, PEF <25%). Present the treatment protocol: repeated SABA nebulization, ipratropium, early systemic corticosteroids, IV magnesium sulfate for severe cases. Include disposition criteria and step-up plan at discharge.
Simple pricing, no surprises
Start free today. Upgrade when your department needs more.
Free
Try SlideCraft with no commitment
- 2 decks per month
- AI slides with speaker notes
- View & present only (no export)
- 7-day cloud storage
- Slide Checker & Outline Generator
Pro
For clinicians who lecture weekly
- 10 decks/mo + $2.50/extra
- AI Critic Mode (5-axis review)
- Document-to-deck (PDF upload)
- PDF, PPTX, SCORM & image export
- Permanent cloud storage
Expert
For academic physicians who publish and present
- 25 decks/mo + $2.00/extra
- PubMed source verification
- Paper-to-deck pipeline
- Auto-citations (Vancouver)
- Everything in Pro